NO20000085L - Forbedrede fremgangsmåter og preparater for behandling av ereksjonsdysfunksjon hos menn - Google Patents

Forbedrede fremgangsmåter og preparater for behandling av ereksjonsdysfunksjon hos menn

Info

Publication number
NO20000085L
NO20000085L NO20000085A NO20000085A NO20000085L NO 20000085 L NO20000085 L NO 20000085L NO 20000085 A NO20000085 A NO 20000085A NO 20000085 A NO20000085 A NO 20000085A NO 20000085 L NO20000085 L NO 20000085L
Authority
NO
Norway
Prior art keywords
men
treatment
erectile dysfunction
preparations
improved methods
Prior art date
Application number
NO20000085A
Other languages
English (en)
Other versions
NO20000085D0 (no
Inventor
Gary Neal
Original Assignee
Androsolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/890,445 external-priority patent/US6103765A/en
Application filed by Androsolutions Inc filed Critical Androsolutions Inc
Publication of NO20000085D0 publication Critical patent/NO20000085D0/no
Publication of NO20000085L publication Critical patent/NO20000085L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Tilførsel av en farmasøytisk preparat i form av et suppositorium omfattende: (a) et vasodilaterende prostaglanding, (b) en 15-hydroksyprostaglandin- dehydrogenaseinhibitor og (c) et basisk materiale som er fast ved romtemperatur og som frigir bestanddelene (a) og (b) ved innsetting i urethra eller meatus, er effektivt for behandling av ereksjonsdysfunksjon hos menn.
NO20000085A 1997-07-09 2000-01-07 Forbedrede fremgangsmåter og preparater for behandling av ereksjonsdysfunksjon hos menn NO20000085L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/890,445 US6103765A (en) 1997-07-09 1997-07-09 Methods for treating male erectile dysfunction
US6829497P 1997-12-19 1997-12-19
PCT/US1998/013439 WO1999002147A1 (en) 1997-07-09 1998-07-09 Improved methods and compositions for treating male erectile dysfunction

Publications (2)

Publication Number Publication Date
NO20000085D0 NO20000085D0 (no) 2000-01-07
NO20000085L true NO20000085L (no) 2000-03-01

Family

ID=26748814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000085A NO20000085L (no) 1997-07-09 2000-01-07 Forbedrede fremgangsmåter og preparater for behandling av ereksjonsdysfunksjon hos menn

Country Status (8)

Country Link
US (2) US6414027B1 (no)
EP (1) EP1005336A4 (no)
JP (1) JP2001509480A (no)
KR (1) KR20010021625A (no)
AU (1) AU742787B2 (no)
CA (1) CA2295595A1 (no)
NO (1) NO20000085L (no)
WO (1) WO1999002147A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6676682B1 (en) * 1997-05-08 2004-01-13 Scimed Life Systems, Inc. Percutaneous catheter and guidewire having filter and medical device deployment capabilities
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
EP1214039A2 (en) * 1999-09-09 2002-06-19 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
SG99857A1 (en) 1999-11-18 2003-11-27 Univ Singapore A method of treatment and prophylaxis
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
EP1762236B1 (en) * 2000-05-12 2015-07-15 Septodont Holding SAS Formulations of alpha adrenergic receptor antagonists and their uses
CA2482711A1 (fr) * 2002-04-23 2003-11-06 L'oreal Composition cosmetique pour favoriser la pousse et/ou empecher ou retarder la chute des cheveux
US7320967B2 (en) * 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
EP1380630A3 (en) * 2002-07-11 2004-01-28 Herbal Apothecary Limited Hydrocarbon wetting and separation agent
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
US8287474B1 (en) 2002-08-22 2012-10-16 Koenig J Frank Method and apparatus for noninvasively increasing whole body blood flow and noninvasive physical exercise of limbs from the outside and from within the limb to treat diseases throughout the body
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
EP1594438B1 (fr) * 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
EP1642584A1 (en) * 2003-06-25 2006-04-05 Cardiovascular Institute, Ltd External preparation for improving coital function
JP4837896B2 (ja) * 2004-03-31 2011-12-14 焼津水産化学工業株式会社 精力増強剤
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
DE102006031758A1 (de) * 2006-07-04 2008-01-10 Kilic, Cuma Zusammensetzung zur Verminderung der Eindringtiefe von Körperflüssigkeiten in die Harnröhre
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US7975699B2 (en) 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US20090110933A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices related to nitric oxide releasing materials
US20110190604A1 (en) * 2006-12-22 2011-08-04 Hyde Roderick A Nitric oxide sensors and systems
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
CN101808642B (zh) * 2007-09-28 2012-05-02 布里格海姆妇女医院公司 肥大细胞稳定剂治疗肥胖症
US8349262B2 (en) * 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US20090112193A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices that utilize photolyzable nitric oxide donors
US8877508B2 (en) * 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
PL3089732T3 (pl) * 2013-12-31 2023-12-27 Pb&B Sa Kompozycje o kontrolowanym uwalnianiu kwasów tłuszczowych do stosowania w rekonstrukcji i kształtowaniu sylwetki
AU2016205336A1 (en) 2015-01-06 2017-08-03 Venturis Therapeutics, Inc. Angiogenic treatment of ischemic heart disease
AU2016220304B2 (en) * 2015-02-16 2019-07-25 Venturis Therapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
CN107375612A (zh) * 2017-08-30 2017-11-24 南宁学院 一种治疗白尿病的药酒及其制备方法
CN107714704A (zh) * 2017-09-19 2018-02-23 陈有平 西地那非与2‑甲氧基‑3‑氧代‑18β‑齐墩果烷‑1,12‑二烯‑30‑酸咀嚼片
CN107595856A (zh) * 2017-10-11 2018-01-19 陈有平 甘草次酸衍生物与伐地那非复方咀嚼片
CN107595848A (zh) * 2017-10-11 2018-01-19 陈有平 他达拉非口服制剂
CN107595855A (zh) * 2017-10-11 2018-01-19 陈有平 伐地那非口服制剂
CN107468663A (zh) * 2017-10-11 2017-12-15 陈有平 他达拉非与甘草次酸衍生物的复方咀嚼片
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
RU2727506C1 (ru) * 2019-09-09 2020-07-22 Пивипи Лабс Пте. Лтд. Средство для лечения эректильной дисфункции

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3070623A (en) 1957-07-16 1962-12-25 Biorex Laboratories Ltd Pharmacological compounds
AT290523B (de) 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
US3967618A (en) 1969-04-01 1976-07-06 Alza Corporation Drug delivery device
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US3654349A (en) 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US3657327A (en) 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3800038A (en) 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US3781429A (en) 1972-09-29 1973-12-25 American Cyanamid Co Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US3911124A (en) * 1974-01-28 1975-10-07 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3928588A (en) 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3965143A (en) 1974-03-26 1976-06-22 G. D. Searle & Co. 16-Oxygenated prostanoic acid derivatives
US4060691A (en) 1974-03-26 1977-11-29 G. D. Searle & Co. 7-{3-Hydroxy-2-[4-hydroxy-4-(lower alkyl)-trans-1-octen-1-yl]-5-oxocyclopent-1-yl}heptanoic acids and esters
US4014987A (en) 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US3976660A (en) * 1974-08-15 1976-08-24 E. R. Squibb & Sons, Inc. Pyrrolidine derivatives
US4112942A (en) 1974-10-09 1978-09-12 Reckitt & Colman Products Limited Method of preparing and administering a foam enema
US4038415A (en) * 1975-08-07 1977-07-26 Nelson Research & Development Company Prostaglandin dehydrogenase inhibiting agents
US4198406A (en) 1975-11-27 1980-04-15 Beecham Group Limited Carbamoyl heterocyclicthio cephalosporins and pharmaceutical compositions formulated therewith
US4128577A (en) 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
JPS5297950A (en) 1976-02-13 1977-08-17 Taisho Pharmaceut Co Ltd Chalconeether derivatives
CA1097239A (en) 1976-05-11 1981-03-10 Salvador Moncada Enzymatic preparation of prostacyclin and its salts
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4215128A (en) 1977-09-20 1980-07-29 Beecham Group Limited Clavulanic acid derivatives their preparation and use
US4178457A (en) 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
SE431821B (sv) 1979-01-29 1984-03-05 Perstorp Ab Lagringsstabilt, prostaglandininnehallande medicinskt preparat
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4271314A (en) 1979-11-28 1981-06-02 G. D. Searle & Co. 4,5-Unsaturated prostanoic acid derivatives
DE3126924A1 (de) 1981-07-03 1983-01-20 Schering Ag, 1000 Berlin Und 4619 Bergkamen 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel
ZA831186B (en) 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
US4961931A (en) 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4564362A (en) 1983-07-07 1986-01-14 Burnhill Michael S Vaginal device
US4521421A (en) 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
JPH0818989B2 (ja) 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
US4503040A (en) 1984-02-27 1985-03-05 Pfizer Inc. 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4507323A (en) 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4683328A (en) 1985-11-25 1987-07-28 G. D. Searle & Co. Tetraenyl prostaglandins
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
FR2599260A1 (fr) 1986-04-24 1987-12-04 Centre Nat Rech Scient Dispositif implantable rechargeable pour auto-injection dosee et repetee de medicament.
US4766889A (en) 1986-06-26 1988-08-30 Medical Engineering Corporation Infusion erectile system
US4829991A (en) 1987-01-06 1989-05-16 Medical Engineering Corp. Method and device for stimulating an erection
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5015431A (en) 1988-02-04 1991-05-14 The Kendall Company Process for making model skin
US5049384A (en) 1988-07-08 1991-09-17 Kim Young S Antibacterial composition for medical use and a process for the preparation thereof
IL87055A (en) 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
EP0527887B1 (en) 1990-05-03 1995-04-26 G.D. Searle & Co. Pharmaceutical composition
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9012469D0 (en) 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
US4976692A (en) 1990-09-13 1990-12-11 Travenol Laboratories (Israel) Ltd. Catheter particularly useful for inducing labor and/or for the application of a pharmaceutical substance to the cervix of the uterus
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
AU2300092A (en) 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
US5646181A (en) 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5631284A (en) 1993-10-06 1997-05-20 University Of British Columbia Compositions and methods for relaxing smooth muscles
KR100335549B1 (ko) 1993-10-27 2002-11-29 파마시아 앤드 업존 캄파니 안정화된프로스타글란딘e1
US5482039A (en) 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
ES2143049T3 (es) 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
US5601343A (en) 1994-08-31 1997-02-11 Hoffken; Rudiger Unitary wheel system for road vehicles
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5571118A (en) 1995-01-05 1996-11-05 Boutos; David Apparatus for stimulating penile, scrotal, anal, vaginal and clitoral tissue
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
CA2215307A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
US5612314A (en) 1995-04-21 1997-03-18 Brigham & Women's Hospital Nitrosylated neuropeptides
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5718917A (en) 1995-12-15 1998-02-17 Harvard Scientific Corporation PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
US5855548A (en) 1996-06-14 1999-01-05 Vivus, Incorporated Venous flow control element for maintaining penile erection
AU3588797A (en) 1996-07-03 1998-01-21 Board Of Regents Of The University Of Oklahoma, The Enhancement of skin pigmentation by prostaglandins
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US5925629A (en) 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
JP2003525845A (ja) 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US5919474A (en) 1997-10-28 1999-07-06 Vivus, Inc. Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith
US5891915A (en) 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor

Also Published As

Publication number Publication date
US6414027B1 (en) 2002-07-02
US6559184B2 (en) 2003-05-06
KR20010021625A (ko) 2001-03-15
CA2295595A1 (en) 1999-01-21
US20020128314A1 (en) 2002-09-12
NO20000085D0 (no) 2000-01-07
JP2001509480A (ja) 2001-07-24
AU742787B2 (en) 2002-01-10
AU8473498A (en) 1999-02-08
EP1005336A4 (en) 2001-01-17
EP1005336A1 (en) 2000-06-07
WO1999002147A1 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
NO20000085L (no) Forbedrede fremgangsmåter og preparater for behandling av ereksjonsdysfunksjon hos menn
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
BR9811099A (pt) Inibidores de urocinase
NO20025585L (no) Inhibitorer for 11-beta-hydroxy steroid dehydrogenase type 1
DK1076657T3 (da) Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
DK1017692T3 (da) 4-Heteroaryl-tetrahydroquinoliner og deres anvendelse som inhibitorer af cholesterolester-transferproteiner
BR9914163A (pt) Agente para melhorar a potência excretora da bexiga urinária, uso de um composto de amina do tipo não carbamato que tenha uma ação inibidora de acetilcolinesterase, e, método para melhorar a potência excretora da bexiga urinária
DK1242438T3 (da) Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
DK0779807T3 (da) Fremgangsmåde til fremstilling af en kappetablet med spids kerne
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
NO20000265D0 (no) Kontrollert cytolyse av målceller, midler og sammensetninger som forårsaker cytolyse og forbindelser som kan anvendes for å fremstille midlene
BR9910864A (pt) Compostos anti-inflamatórios para inibição de aderência celular
EP1411118A4 (en) Cell proliferation inhibitors with anti-glycanic-3 antibody
NO20003600L (no) Kalium kanal inhibitorer
BR0008309A (pt) Processo de criar uma superfìcie de concreto com padrão com o auxìlio de um agente retardador de superfìcie de concreto
DK0968719T3 (da) Enzymsammensætning, der er i stand til at danne et oligosaccharid in vivo
PT784677E (pt) Inibidor da proliferacaode celulas estaminais e suas utilizacoes
DK1161235T3 (da) Kombinationer til behandling af sygdomme, der involverer angiogenese
NO953763L (no) Heterocykel-holdige amidin-derivater, deres fremstilling og anvendelse
NO994431L (no) Ny formulering
WO2001034172A3 (en) Methods and compositions for treating reward deficiency syndrome
MXPA99002575A (es) Composicion para la inhibicion viral, que comprende amidas, acidos grasos, alcanos y alcoholes de cadena larga.
MX9701776A (es) Uso de factores de crecimiento similares a insulina i y ii para la inhibicion de la respuesta inflamatoria.
NZ330244A (en) Isoxazole derivatives useful in the treatment of inflammatory diseases